Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BIOA-B.ST
- Price
- 164.60
- Stock movement up
- +2.60 (1.60%)
- Company name
- BioArctic AB (publ)
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 12.18B
- Ent value
- 11.75B
- Price/Sales
- 72.86
- Price/Book
- 13.26
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 46.54
- PEG
- -
- EPS growth
- -9.78%
- 1 year return
- -19.79%
- 3 year return
- 14.97%
- 5 year return
- 18.31%
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
BIOA-B.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 72.86 |
| Price to Book | 13.26 |
| EV to Sales | 70.29 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 73.99M |
| EPS (TTM) | -2.64 |
| FCF per share (TTM) | -1.91 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 167.14M |
| Gross profit (TTM) | 89.83M |
| Operating income (TTM) | -254.67M |
| Net income (TTM) | -232.86M |
| EPS (TTM) | -2.64 |
| EPS (1y forward) | 3.54 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 53.74% |
| Operating margin (TTM) | -152.37% |
| Profit margin (TTM) | -139.32% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 604.47M |
| Net receivables | 0.00 |
| Total current assets | 989.72M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 1.09B |
| Accounts payable | 0.00 |
| Short/Current long term debt | 56.38M |
| Total current liabilities | 118.51M |
| Total liabilities | 174.44M |
| Shareholder's equity | 918.63M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -161.53M |
| Capital expenditures (TTM) | 7.44M |
| Free cash flow (TTM) | -168.98M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -25.35% |
| Return on Assets | -21.30% |
| Return on Invested Capital | -25.00% |
| Cash Return on Invested Capital | -18.14% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 163.30 |
| Daily high | 164.60 |
| Daily low | 158.40 |
| Daily Volume | 153K |
| All-time high | 377.80 |
| 1y analyst estimate | 322.00 |
| Beta | -0.25 |
| EPS (TTM) | -2.64 |
| Dividend per share | - |
| Ex-div date | 10 May 2019 |
| Next earnings date | 15 May 2025 |
Downside potential
Loading...
Downside potential data
| BIOA-B.ST | S&P500 | |
| Current price drop from All-time high | -56.43% | -12.89% |
| Highest price drop | -69.35% | -56.47% |
| Date of highest drop | 23 Mar 2020 | 9 Mar 2009 |
| Avg drop from high | -35.73% | -11.07% |
| Avg time to new high | 94 days | 12 days |
| Max time to new high | 803 days | 1805 days |
COMPANY DETAILS
Marketcap
12.18B
Marketcap category
Large-cap
Description
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Employees
96
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
As European markets grapple with the fallout from higher-than-expected U.S. trade tariffs, which have led to significant declines in major indices like the STOXX Europe 600 and Germany's DAX, investor...
April 9, 2025
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer the marketing authorisation approval decision of lecanemab in the ...
April 1, 2025
As European markets experience a mix of modest gains and losses, with the pan-European STOXX Europe 600 Index rising slightly amid hopes for increased government spending, investors are navigating a l...
March 27, 2025
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment o...
March 17, 2025
Amidst a backdrop of global economic uncertainty, the European market has shown resilience with mixed returns across major stock indexes, as the pan-European STOXX Europe 600 Index ended slightly lowe...
March 11, 2025
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its ...
February 28, 2025
In the midst of geopolitical tensions and shifting consumer spending patterns, global markets have experienced a volatile week, with major U.S. indexes seeing early gains erased by sharp losses later ...
February 25, 2025
As global markets grapple with trade uncertainties and mixed economic signals, with the S&P 500 showing resilience despite tariff concerns, investors are keenly observing sectors that can weather such...
February 10, 2025
As global markets navigate a landscape marked by political developments and economic shifts, U.S. stocks have surged to record highs, fueled by optimism over trade policies and advancements in artific...
January 27, 2025
As global markets continue to react to political developments and economic indicators, U.S. stocks have been marching toward record highs, buoyed by optimism around softer tariffs and artificial intel...
January 27, 2025
Next page